evipedia.ai
← Back

MOTS-c for Health & Longevity

Evidence Review created on 10/28/2026 using AI4L / Opus 5.5

Also known as: Mitochondrial Open Reading Frame of the 12S rRNA-c, Mitochondrial Open Reading Frame of the 12S rRNA Type-c, MOTSc, MOTs-C, MOTS-c Acetate

Motivation

MOTS-c is a short protein made from instructions stored in the energy-producing parts of the cell, the mitochondria, rather than in the cell nucleus. It belongs to a recently discovered family of such signals. Laboratory work studies its role in how muscle handles sugar and fat, which is why it has been described as an exercise-like molecule. It is now sold as an injectable product in clinics and online, outside approved medical channels.

Interest grew as mouse experiments examined its effects on blood sugar control, body fat and physical performance in old age, and as researchers measured the body’s own levels during exercise and across ages and metabolic states. A drug company tested a modified version in people, and in 2026 a federal advisory panel debated whether pharmacies may prepare it.

This review examines what is known about MOTS-c for health-oriented adults: how it is thought to work, the human and animal evidence on benefits and harms, product quality and legal status, and the open questions that current studies are designed to answer.

Benefits - Risks - Protocol - Conclusion

High-level narrative reviews and expert commentary that explain MOTS-c biology, its aging relevance, exercise links and safety gaps.

No directly relevant content was found from Rhonda Patrick, Andrew Huberman, Chris Kresser or Life Extension; Peter Attia’s MOTS-c analysis is member-only, so it cannot be listed as an openly accessible item; Chris Kresser’s site and Lifespan.io returned only passing mentions in a broad podcast episode and a monthly news digest, which do not discuss MOTS-c in depth.

Grokipedia

MOTS-c

AI-written encyclopedia entry covering discovery, structure, metabolic and exercise-mimetic functions, preclinical and clinical research, safety, regulatory status and controversies; useful orientation, though its claims are not independently verified.

Examine

No Examine article on MOTS-c exists.

ConsumerLab

No ConsumerLab article on MOTS-c exists.

Systematic Reviews

The only two systematic reviews that cover MOTS-c, both on the body’s own circulating levels rather than on MOTS-c given as a treatment.

No systematic review or meta-analysis has assessed the risks of MOTS-c given as a treatment; the risk side of the trade-off is unrepresented.

Mechanism of Action

MOTS-c is a 16-amino-acid peptide encoded in the 12S rRNA gene (a ribosomal RNA gene) of mitochondrial DNA. Its discoverers, whose senior author co-founded CohBar, a company developing mitochondrial peptides (USC faculty page), found that skeletal muscle is its main target in mice, where it inhibits the folate cycle (the vitamin B9–dependent pathway supplying DNA building blocks), allowing AICAR (an internal metabolite) to accumulate and switch on AMPK (AMP-activated protein kinase, the cell’s energy sensor) (Lee 2015). Downstream, glucose uptake and fat oxidation (the breakdown of fat for energy) rise.

  • Nuclear signaling: under metabolic stress MOTS-c moves into the nucleus and switches on stress-defense genes controlled by NRF2 (a master switch for antioxidant genes) (Kim 2018).
  • Muscle targets: it binds and activates CK2 (casein kinase 2, a signaling enzyme) (Kumagai 2024), restraining myostatin (a protein that limits muscle growth) (Kumagai 2021), and improves mitochondrial efficiency through PGC-1α (a regulator of mitochondrial growth) (Gudiksen 2026).
  • Competing interpretations: in cultured aged cells MOTS-c modestly increased inflammatory secretions (Kim 2018), and human limb-blood sampling suggests exercising muscle may not be the source of circulating MOTS-c (Gudiksen 2026).
  • Pharmacology: no human half-life, tissue-distribution or metabolism study of native MOTS-c is published; it circulates in plasma and enters cell nuclei, and it is presumed to be broken down by protein-cleaving enzymes, and laboratory incubation identified four breakdown products and two oxidation products (Knoop 2019). Selectivity beyond AMPK and CK2 is uncharacterized.

Historical Context & Evolution

MOTS-c was not developed as a drug; it was discovered. After humanin (another peptide encoded in mitochondrial DNA) was found in 2001, the University of Southern California group led by Pinchas Cohen searched mitochondrial DNA for further short genes and in 2015 reported MOTS-c as a regulator of insulin sensitivity that prevented diet-induced obesity in mice (Lee 2015). Because Cohen co-founded CohBar, a company developing mitochondrial peptides (USC faculty page), much of the founding literature comes from researchers with a financial interest in the peptide.

Health-optimization interest followed three findings. Japanese researchers proposed that a MOTS-c gene variant common in Northeast Asians might contribute to exceptional longevity (Fuku 2015); a later analysis of 736 centenarians found the variant no more common than in controls (Zempo 2021). A 2021 study reported that exercise raises MOTS-c in human muscle and that late-life treatment improved physical capacity in old mice (Reynolds 2021). CohBar’s analog CB4211 completed a first human trial in 2021 (NCT03998514).

Regulatory views shifted: FDA (U.S. Food and Drug Administration) placed MOTS-c among peptides with potential safety risks for compounding; the nomination was later withdrawn and the substance moved to FDA’s withdrawn list (FDA Category 2 page), and in 2026 an FDA advisory committee reconsidered it (FDA advisory committee meeting page). Meanwhile WADA (World Anti-Doping Agency) added it to the 2025 Prohibited List, as announced by the U.S. Anti-Doping Agency (USADA advisory).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no human trial of MOTS-c itself has reported a clinical endpoint, and the only interventional human data come from one small trial of a modified analog.

Medium 🟩 🟩

No benefit reaches Medium: all human evidence is indirect (an analog compound, a gene variant, or the body’s own circulating levels), which caps grades at Low.

Low 🟩

Blood Glucose Control and Insulin Sensitivity ⚠️ Conflicted

MOTS-c reversed insulin resistance (reduced cellular response to insulin) in mice (Lee 2015). Human data are indirect: an analog lowered glucose, and men with a less active variant had more type 2 diabetes (Zempo 2021). Levels are low in diabetes, high in obesity (Zhou 2024). Net: plausible but unconfirmed.

Magnitude: Glucose fell 6 percentage points more than placebo (−6% vs. 0%) after four weeks of the analog CB4211, 25 mg daily (n = 11 vs. 9; no 95% CI (confidence interval, the range likely to contain the true effect) reported; company-reported) (CohBar press release).

Liver Enzyme Reduction in Fatty Liver Disease

In adults with obesity and fatty liver disease, four weeks of the analog CB4211 lowered ALT and AST (liver enzymes released when liver cells are injured), but liver fat fell equally with placebo. Evidence is indirect (analog), company-reported and not peer-reviewed; MOTS-c reduced fatty liver in mice (Kim 2019).

Magnitude: ALT changed −21% vs. +4% with placebo (difference 25 percentage points) and AST −28% vs. −11% (difference 17 points); liver fat fell 5.03 vs. 4.88 percentage points (not compared between groups) (CohBar press release).

MOTS-c improved running in old mice, and late-life intermittent treatment improved grip strength and gait (Reynolds 2021). Human data are indirect: exercise raises muscle MOTS-c (Reynolds 2021), and men carrying a less active variant showed higher sarcopenia (age-related muscle loss) risk (Kumagai 2024).

Magnitude: In old mice, two weeks of daily MOTS-c doubled treadmill running time (2-fold) and increased distance 2.16-fold vs. untreated mice; no human study has given MOTS-c and measured strength or physical function (Reynolds 2021).

Body Fat Reduction

MOTS-c prevented diet-induced fat gain in mice (Lee 2015). The only human data are indirect: four weeks of the analog CB4211 produced a non-significant trend toward lower weight in adults with obesity (CohBar press release). Circulating MOTS-c is higher with abdominal and liver fat (Sequeira 2021).

Magnitude: Direction only: MOTS-c curbed fat gain in high-fat-fed and old mice (Reynolds 2021), and the analog trial reported a weight “trend”; the literature reports no human outcome figure for fat or weight.

Lifespan Extension ⚠️ Conflicted

A MOTS-c gene variant, proposed to explain Japanese longevity (Fuku 2015), was no more common in 736 centenarians than controls (Zempo 2021). Late-life treatment of mice gave a non-significant lifespan trend (Reynolds 2021). Evidence is indirect (variant and mouse data, not administered MOTS-c in people). Net: no reliable lifespan signal.

Magnitude: Variant frequency was 7.7% in centenarians vs. 7.5% in controls (no enrichment); no human study has measured survival with MOTS-c treatment (Zempo 2021).

Blood Vessel and Heart Health ⚠️ Conflicted

Evidence is indirect: the body’s own levels, not administered MOTS-c. Low levels accompanied endothelial dysfunction (impaired blood-vessel lining) (Qin 2018) and predicted cardiac events in diabetes (Ikonomidis 2020), yet were higher in acute coronary syndrome (heart attack or unstable angina) (Cao 2025). Net: levels track cardiovascular stress inconsistently.

Magnitude: In 121 people with diabetes and coronary disease, MOTS-c below 167 ng/mL carried a relative risk (event risk compared with the reference group) of 3.8 for cardiac events over two years (observational; no 95% CI reported in the abstract; not an effect of administered MOTS-c) (Ikonomidis 2020).

Speculative 🟨

Bone Loss Prevention

In mice after ovariectomy (removal of the ovaries, a menopause model), daily MOTS-c for 12 weeks reduced bone loss by blocking bone-resorbing cells (Ming 2016). Basis is animal data only.

Pancreatic Islet Protection

MOTS-c reduced autoimmune destruction of insulin-producing cells in diabetes-prone mice (Kong 2021) and slowed aging of these cells (Kong 2025). Basis is animal and cell data only.

Benefit-Modifying Factors

  • Genetic variant (m.1382A>C): carriers of m.1382A>C (a mitochondrial DNA variant common in Northeast Asians that swaps one amino acid in MOTS-c, weakening its action) show nearly 20-fold higher measured levels, possibly compensatory (Zempo 2021). Response to added MOTS-c in carriers is untested.
  • Baseline metabolic status: mouse benefits appeared mainly under high-fat feeding or old age (Lee 2015); the ongoing human trial targets prediabetes with overweight (NCT07505745). Metabolically healthy, trained adults may gain less.
  • Sex: female mice on a high-fat diet showed no weight or glucose response to MOTS-c, and the variant’s diabetes link was male-specific (Zempo 2021).
  • Pre-existing conditions: circulating MOTS-c is lower in type 2 and type 1 diabetes (Zhou 2024; Kong 2021); whether low levels predict a larger response is unknown.
  • Age: plasma MOTS-c falls with age while muscle levels rise in older men (D’Souza 2020); old mice responded robustly (Reynolds 2021), but no data exist in older humans.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no human trial of MOTS-c itself has reported adverse events, and no multi-group human safety data exist.

Medium 🟥 🟥

No risk reaches Medium: the only human adverse-event data come from an analog (CB4211) in a single company-reported trial, which caps grades at Low.

Low 🟥

Injection-Site Reactions

Transient, mostly mild-to-moderate injection-site reactions were the only adverse events in more than 10% of CB4211 recipients; no serious adverse events occurred. Evidence is indirect (analog, four weeks, company-reported). Reviews note scarce human safety data for gray-market peptides (Mendias 2026).

Magnitude: More than 10% of CB4211 recipients (25 mg daily for four weeks; n = 11); the release gives no placebo rate (CohBar press release).

Speculative 🟨

Immune Reactions and Product Impurities

FDA warns of immunogenicity (tendency to provoke an immune response) and impurity risks, citing no human exposure data (FDA Category 2 page). Basis is regulatory concern and one clinician’s anecdote (Healio report).

Low Blood Sugar With Glucose-Lowering Drugs

MOTS-c lowers glucose through AMPK in mice (Lee 2015); adding it to insulin or insulin-releasing drugs could cause hypoglycemia (low blood sugar). Basis is mechanistic; no human case reported.

Increased Inflammatory Signals From Aged Cells

In cultured senescent (aged, non-dividing) human cells, MOTS-c modestly increased selected inflammatory secretions (Kim 2018). Basis is cell-culture data only; relevance to people is unknown.

Risk-Modifying Factors

  • Genetic variant (m.1382A>C): carriers already have high circulating levels of a less active MOTS-c form (Zempo 2021); whether added native peptide changes risk in them is unknown.
  • Baseline glucose: people with normal or low fasting glucose, or tight diabetes control, have least margin against glucose lowering; the analog lowered glucose by about 6% in four weeks (CohBar press release).
  • Sex: no human sex-specific safety data exist; female mice showed no metabolic response (Zempo 2021), so sex differences in effect, and possibly in side effects, are plausible but untested.
  • Pre-existing conditions: diabetes treated with insulin or sulfonylureas (drugs that force insulin release) raises hypoglycemia risk; known allergy to peptide drugs raises concern given FDA’s immunogenicity warning (FDA Category 2 page).
  • Age: no safety data exist above age 65; the ongoing trial enrolls 18–65 (NCT07505745). Older adults more often take glucose-lowering drugs and multiple medications.

Key Interactions & Contraindications

Documented interactions:

  • Metformin (glucose-lowering drug): in a randomized trial of women with breast cancer, 24 weeks of metformin did not change circulating MOTS-c (Cuyàs 2022); no interaction found on the body’s own levels. Pairing with administered MOTS-c is untested.
  • Competitive sport (anti-doping rules): MOTS-c is on the Prohibited List as an AMPK activator; a positive test causes an anti-doping violation for tested athletes (USADA advisory; WADA Prohibited List). Avoid.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Insulin and sulfonylureas (glipizide, glimepiride): additive glucose lowering via AMPK-driven muscle glucose uptake; consequence is hypoglycemia. Mitigation: frequent glucose checks.
  • Other glucose-lowering drug classes: metformin (shared AMPK activation) and GLP-1 receptor agonists (drugs mimicking a gut hormone that lowers glucose and appetite; semaglutide, tirzepatide); consequence is additive glucose lowering. Mitigation: glucose monitoring.
  • Antifolate drugs (drugs that block folate use by cells; methotrexate, pemetrexed): MOTS-c inhibits the folate cycle, so effects could add; consequence is unknown, possibly greater folate-pathway suppression. Mitigation: combine only after prescriber review.
  • Over-the-counter medications: none identified; no common over-the-counter drug shares a known MOTS-c mechanism.
  • AMPK-activating supplements (berberine, alpha-lipoic acid): additive AMPK activation and glucose lowering; consequence is lower glucose. Mitigation: introduce one agent at a time and monitor glucose.
  • High-dose folic acid or folinic acid: could theoretically offset folate-cycle inhibition and blunt MOTS-c effects; consequence is reduced effect.
  • Exercise: a review concludes that mouse studies show partly overlapping pathways for MOTS-c and exercise (Woodhead 2021); combined effects on glucose could be additive.

Populations who should avoid MOTS-c:

  • Athletes subject to anti-doping testing (on the WADA Prohibited List; USADA advisory).
  • People with a history of allergic reactions to peptide drugs (inferred from FDA’s immunogenicity concern; no human data; FDA Category 2 page).
  • Pregnant or breastfeeding women (inferred from AMPK activation and folate-cycle inhibition during fetal and infant growth, which depends on folate; no human data; FDA Category 2 page reports no human exposure data).
  • Children and adolescents (inferred from folate-cycle inhibition and AMPK-driven metabolic shifts in growing tissue; no human data).
  • People with diabetes using insulin or sulfonylureas without glucose monitoring (inferred from glucose-lowering mechanism; no human data).

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Verified sourcing: a certificate of analysis and an FDA-registered manufacturer meet FDA’s quality requirements for compounding ingredients, though not its listing requirement (FDA compounding page); mitigates contamination, mislabeling and impurity-driven immune reactions.
  • Sterile injection technique: single-use needles, alcohol swabs and rotating injection sites; mitigates injection-site reactions and infection.
  • Glucose checks with glucose-lowering drugs: daily fingerstick or continuous monitoring for 1–2 weeks; medical advice is sought below 70 mg/dL, the American Diabetes Association hypoglycemia threshold (earns nothing from MOTS-c) (American Diabetes Association Standards of Care 2026); prevents unnoticed hypoglycemia.
  • Stopping at allergic signs: use is discontinued at hives, spreading redness, facial swelling or breathing difficulty; mitigates escalation of immune reactions flagged by FDA.
  • Baseline and follow-up labs: fasting glucose, HbA1c (average blood sugar over about three months), ALT and AST before starting and at four weeks; detects unexpected glucose or liver changes.
  • Time-limited courses: short courses (4–8 weeks) with breaks limit cumulative exposure to a compound without long-term human safety data.
  • Sport eligibility check: anti-doping status is confirmed before use; mitigates a sanction under WADA rules (USADA advisory).

Therapeutic Protocol

Timing, cycling and titration parameters without a citation reflect common practice; no validated human dose of native MOTS-c exists.

  • Gray-market community protocol: 5–10 mg subcutaneously (under the skin) three times weekly, or 1–2 mg daily, per a commercial biohacking site summarizing user practice (Outliyr MOTS-c report); not trial-validated.
  • Analog trial regimen: CB4211 25 mg subcutaneously once daily for four weeks (CohBar press release); an analog, not dose-equivalent to MOTS-c.
  • Ongoing native-peptide trial: fixed once-daily subcutaneous dose for 12 weeks, dose undisclosed (NCT07505745).
  • Animal dosing: 5–15 mg/kg daily by intraperitoneal (abdominal-cavity) injection, or three times weekly late in life (Reynolds 2021).
  • Popularizers: use spread through peptide clinics and online communities; no named practitioner has published a protocol, and the discoverer’s company pursued an analog instead.
  • Time of day: no human data; morning or pre-exercise dosing is common because exercise raises the body’s own MOTS-c (Reynolds 2021).
  • Half-life: unknown in humans; no pharmacokinetic study of native MOTS-c is published. In mice the variant form cleared 2.6 times slower than native MOTS-c (Zempo 2021).
  • Single vs. split dosing: protocols use one injection per dosing day; no data support splitting.
  • Genetics: carriers of the m.1382A>C variant produce a less active MOTS-c (Zempo 2021); whether they need different dosing is untested.
  • Sex: male but not female mice responded metabolically (Zempo 2021); no human sex-specific dosing data exist.
  • Age: old mice responded (Reynolds 2021); no dosing data exist for adults over 65, where lower starting doses are common practice.
  • Baseline biomarkers: insulin resistance (reduced cellular response to insulin) is the trial target population (NCT07505745); normal-glucose users have less to gain.
  • Pre-existing conditions: people on insulin or sulfonylureas typically start low with glucose monitoring; fatty liver disease is the condition with analog data.

Discontinuation & Cycling

  • Short-term use: all human and community regimens are time-limited (4–12 weeks); no data support lifelong use (NCT07505745).
  • Withdrawal effects: none reported; no human study has followed people after stopping native MOTS-c.
  • Tapering: not applicable; no dependence or rebound mechanism is known, so abrupt stopping is standard.
  • Cycling: common practice is 4–8 weeks on followed by a break of similar or longer length; no study shows that cycling preserves effect or that tolerance develops.
  • Feedback on own production: variant carriers’ high levels may reflect compensatory overproduction, suggested by mouse production-rate estimates (Zempo 2021); whether added peptide suppresses natural production is unknown.

Sourcing and Quality

  • Regulatory status of supply: MOTS-c is not FDA-approved. Pharmacies may compound only monograph ingredients, approved-drug components, or 503A bulks list (approved raw-ingredient list) substances (FDA compounding page); MOTS-c is under review (FDA advisory committee meeting page), so most product is sold as a “research chemical.”
  • Compounding outlook: the Pharmacy Compounding Advisory Committee voted 7–5 (2 abstentions) to recommend listing MOTS-c (reported by Healio; FDA minutes not yet posted) (Healio report; FDA advisory committee meeting page); the committee faced scrutiny over members’ conflicts of interest.
  • What to look for: third-party certificate of analysis showing identity by mass spectrometry, high purity by liquid chromatography (commonly 98% or more), endotoxin and sterility testing; FDA cites impurity and characterization concerns (FDA Category 2 page).
  • Forms: MOTS-c is supplied as free base or acetate salt (FDA advisory committee meeting page); doses are usually stated per vial weight without salt correction.
  • Reputable brands: no brand or compounding pharmacy can be named as a verified, lawful United States source while MOTS-c remains off the 503A list (FDA advisory committee meeting page).
  • Storage: freeze-dried powder is typically refrigerated; once mixed with bacteriostatic water, refrigerated use within weeks is common practice.

Practical Considerations

  • Time to effect: mouse metabolic effects appeared within 1–2 weeks (Reynolds 2021); analog liver-enzyme and glucose changes were seen at four weeks (CohBar press release). Human time to effect for native MOTS-c is unknown.
  • Pitfall – treating it as exercise in a vial: a review concludes that MOTS-c and exercise act through partly distinct pathways (Woodhead 2021); mouse benefits do not show that injections replace training.
  • Pitfall – testing blood MOTS-c: antibody-based kits (ELISA, enzyme-linked immunosorbent assays) gave levels that mass spectrometry could not confirm (Knoop 2019), so consumer level tests are unreliable.
  • Pitfall – gray-market quality: unregulated vials may be mislabeled or contaminated; FDA flagged impurity risks (FDA Category 2 page).
  • Regulatory status: not FDA-approved; off the 503A list (FDA compounding page) pending FDA action after a favorable advisory vote (reported by Healio; FDA minutes not yet posted) (Healio report; FDA advisory committee meeting page); prohibited in sport as an AMPK activator (USADA advisory).
  • Cost and access: research-vendor pricing around $100–200 per month plus injection supplies (Outliyr MOTS-c report); not covered by insurers.
  • Payer and funding bias: insurers have no stake in an uncovered peptide; company funding has driven the human trials, from the CohBar analog trial completed in 2021 (NCT03998514) to the Hudson Biotech native-peptide trial started in 2026 (NCT07505745).

Interaction with Foundational Habits

  • Sleep: no direct interaction known; no human study has measured sleep with MOTS-c. Mice showed shifted day–night fuel use with treatment (Reynolds 2021); evening dosing has no rationale.
  • Nutrition: indirect interaction. A fat infusion raised the body’s own MOTS-c, which insulin then blunted (Ramanjaneya 2019); mouse benefits were largest on high-fat diets (Lee 2015). High-dose folate could theoretically blunt its folate-cycle mechanism.
  • Exercise: potentiating, partly overlapping. Cycling raised muscle MOTS-c 11.9-fold and plasma 1.5-fold (no control group) (Reynolds 2021); other trials found only trends (von Walden 2021). Pre-exercise timing is common practice.
  • Stress management: no direct interaction known. MOTS-c responds to metabolic stress such as glucose restriction (Kim 2018), not psychological stress; no cortisol data exist.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes reference points for glucose regulation and liver health, the two areas where analog data show change, and screens out unrecognized diabetes that would change glucose-lowering risk. Body composition by dual-energy X-ray scan provides a baseline for fat-mass claims. Testing circulating MOTS-c is not useful because commercial kits disagree with reference methods (Knoop 2019).

Ongoing monitoring follows this cadence: fasting glucose and liver enzymes at 4 weeks, then every 3 months while using MOTS-c; HbA1c and body composition every 3–6 months. People taking insulin or sulfonylureas add daily glucose checks during the first 1–2 weeks. Success means improved fasting glucose or insulin markers without liver-enzyme rises or injection-site problems; absence of change after a full course suggests no individual benefit.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 70–99 mg/dL (standard reference range) Expected to change; safety check for low glucose Fast 8+ hours; morning draw; pair with fasting insulin; values below 70 mg/dL are the point at which use is stopped and medical advice sought, the American Diabetes Association hypoglycemia threshold (the association earns nothing from MOTS-c) (American Diabetes Association Standards of Care 2026)
Fasting insulin About 2.6–24.9 µIU/mL (standard reference range) Expected to change (insulin sensitivity) Fasting morning draw with glucose; ranges are laboratory-specific; track change from own baseline
HbA1c 4.0–5.6% (standard reference range) Expected to change over months No fasting needed; reflects about three months, so recheck no sooner than 3 months
ALT About 7–55 U/L (standard reference range) Expected to change (analog data); safety check for liver injury Avoid hard exercise 48 hours before; range is laboratory-specific; a rise well above baseline is the point at which use is stopped and medical advice sought
AST About 8–48 U/L (standard reference range) Expected to change (analog data); safety check for liver injury Rises after intense exercise or muscle injury; range is laboratory-specific; pair with ALT
Body fat mass by DEXA No established target; track change from own baseline Expected to change (mouse data) DEXA: dual-energy X-ray absorptiometry; use the same device, hydration and time of day for each scan

Qualitative markers:

  • Injection-site condition (redness, swelling, lumps)
  • Exercise tolerance and perceived endurance
  • Energy levels across the day
  • Signs of low blood sugar (shakiness, sweating, sudden hunger), especially with glucose-lowering drugs
  • Allergic symptoms (hives, itching, facial swelling)

Emerging Research

  • MOTS-MET trial (ongoing): Phase 2a (early efficacy) randomized, placebo-controlled trial of daily MOTS-c for 12 weeks in 120 adults with prediabetes and overweight; primary endpoint Matsuda index (an insulin-sensitivity score) and adverse events; completion 2028 (NCT07505745). Positive: first direct human evidence, raising glucose grading. Null: weakens the central rationale.
  • CB4211 analog trial (completed 2021, no results posted): 88-person Phase 1a/1b (first-in-human safety and dosing) study; topline results are summarized under Benefits and Risks; only a company topline release exists (CohBar press release; NCT03998514). Peer-reviewed publication would allow independent scrutiny of the liver and glucose findings.
  • Diabetes and heart-mortality cohort (registry status unknown, completion 2021; results published 2020, none posted): in 121 people with diabetes and coronary disease, MOTS-c below 167 ng/mL predicted cardiac events (relative risk 3.8) over two years (Ikonomidis 2020; NCT04027712).
  • Assay standardization: antibody tests and mass spectrometry disagree on human MOTS-c levels (Knoop 2019); validated assays could overturn current observational findings, including the obesity–diabetes split in Zhou 2024.
  • Source of circulating MOTS-c: limb-blood sampling suggests muscle may not release it during exercise (Gudiksen 2026), which could weaken the exercise-hormone model.
  • Regulatory decision: FDA rulemaking on the 503A list after the 2026 advisory vote (reported by Healio; FDA minutes not yet posted) would determine pharmacy-grade access (Healio report; FDA advisory committee meeting page).

Conclusion

MOTS-c is a small signaling protein made from genes stored in the cell’s energy-producing parts rather than in its nucleus. In mice it improves blood sugar handling, limits fat gain, protects bone and restores physical capacity in old age, and the body’s own levels rise with exercise. These findings explain the interest from health-focused adults looking for tools that act like exercise at the cellular level.

The human evidence is thin. No study comparing MOTS-c itself with a dummy treatment has reported results. The only human treatment data come from a short, small trial of a modified version, reported by the company that developed it, which showed lower liver enzymes and blood sugar but no clear advantage in liver fat or weight. Studies of the body’s own levels and of a gene variant point in different directions, and the proposed link to exceptional human longevity was not confirmed in a larger group of centenarians.

Safety is largely unknown. Injection-site reactions are the only side effect documented in people, while regulators point to possible immune reactions and impurities in unregulated products. Use is banned in tested sport, and pharmacy access in the United States remains unsettled.

Much of the founding research comes from scientists linked to a company that developed the peptide, and its key human result was released by that company without independent peer review. For now, MOTS-c remains a promising laboratory finding whose value for people is unproven.

Top - Benefits - Risks - Protocol